What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
25
SGMO Quote, Financials, Valuation and Earnings
Last price:
$0.85
Seasonality move
:
-4.44%
Day range:
$0.83 - $0.88
52-week range:
$0.30 - $3.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.94x
P/B ratio:
8.28x
Volume:
3.7M
Avg. volume:
4.7M
1-year change:
30.78%
Market cap:
$188.6M
Revenue:
$57.8M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingSangamo Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Sangamo Therapeutics has an estimated upside of 495.81% from its current price of $0.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.84.
Fair Value
-
According to the consensus of 6 analysts, Sangamo Therapeutics has 495.81% upside to fair value with a price target of $5.00 per share.
SGMO vs. S&P 500
-
Over the past 5 trading days, Sangamo Therapeutics has underperformed the S&P 500 by -2.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sangamo Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sangamo Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Sangamo Therapeutics reported revenues of $7.6M.
Earnings Growth
-
Sangamo Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sangamo Therapeutics reported earnings per share of -$0.11.
Enterprise value:
146.7M
EV / Invested capital:
6.44x
Price / LTM sales:
2.94x
EV / EBIT:
--
EV / Revenue:
2.54x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-2.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-81.59%
Net Income Margin (TTM):
-169.45%
Return On Equity:
-217.48%
Return On Invested Capital:
-217.48%
Operating Margin:
-344.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $111.3M | $176.2M | $57.8M | $2M | $7.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$201.3M | -$119M | -$98.4M | -$61.8M | -$26M | |
| EBITDA | -$180.7M | -$96.8M | -$89.1M | -$58.8M | -$23.9M | |
| Diluted EPS | -$1.25 | -$1.47 | -$0.52 | -$0.34 | -$0.11 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $659.7M | $398.8M | $300.3M | $94.3M | $51.7M | |
| Total Assets | $938.6M | $721.9M | $562.5M | $165.3M | $101.6M | |
| Current Liabilities | $143.5M | $127.9M | $111.7M | $47.7M | $45.8M | |
| Total Liabilities | $441.2M | $346.6M | $267.6M | $82.4M | $78.9M | |
| Total Equity | $497.4M | $375.3M | $295M | $82.9M | $22.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$223.6M | -$224.8M | -$67.1M | -$50.5M | -$3.4M | |
| Cash From Investing | $59.3M | $153.5M | $37.5M | $37.7M | $1.3M | |
| Cash From Financing | $84.7M | $14.6M | $28.4M | $167K | $7M | |
| Free Cash Flow | -$243.8M | -$246M | -$67.4M | -$53.2M | -$3.5M | |
SGMO
Sector
Market Cap
$188.6M
$39.2M
Price % of 52-Week High
26.4%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
-13.35%
-0.81%
1-Year Price Total Return
30.78%
-38.63%
Beta (5-Year)
1.494
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.89
200-day SMA
Sell
Level
$1.15
Bollinger Bands (100)
Sell
Level
0.98 - 2.18
Chaikin Money Flow
Sell
Level
-574.9M
20-day SMA
Sell
Level
$0.93
Relative Strength Index (RSI14)
Sell
Level
38.14
ADX Line
Sell
Level
24.08
Williams %R
Buy
Level
-86.0148
50-day SMA
Sell
Level
$1.06
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
730.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-21.6283)
Sell
CA Score
(Annual)
Level (-4.0989)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.8933)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Stock Forecast FAQ
In the current month, SGMO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SGMO average analyst price target in the past 3 months is $5.00.
-
Where Will Sangamo Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sangamo Therapeutics share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Sangamo Therapeutics?
Analysts are divided on their view about Sangamo Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sangamo Therapeutics is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Sangamo Therapeutics's Price Target?
The price target for Sangamo Therapeutics over the next 1-year time period is forecast to be $5.00 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SGMO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sangamo Therapeutics is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of SGMO?
You can purchase shares of Sangamo Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sangamo Therapeutics shares.
-
What Is The Sangamo Therapeutics Share Price Today?
Sangamo Therapeutics was last trading at $0.85 per share. This represents the most recent stock quote for Sangamo Therapeutics. Yesterday, Sangamo Therapeutics closed at $0.84 per share.
-
How To Buy Sangamo Therapeutics Stock Online?
In order to purchase Sangamo Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.24% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 1.45% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 3.19% over the past day.
